IL143296A0 - Use of human prostate cell lines in cancer treatment - Google Patents

Use of human prostate cell lines in cancer treatment

Info

Publication number
IL143296A0
IL143296A0 IL14329699A IL14329699A IL143296A0 IL 143296 A0 IL143296 A0 IL 143296A0 IL 14329699 A IL14329699 A IL 14329699A IL 14329699 A IL14329699 A IL 14329699A IL 143296 A0 IL143296 A0 IL 143296A0
Authority
IL
Israel
Prior art keywords
cell lines
cancer treatment
human prostate
prostate cell
derivatives
Prior art date
Application number
IL14329699A
Other languages
English (en)
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Publication of IL143296A0 publication Critical patent/IL143296A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
IL14329699A 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment IL143296A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827104.2A GB9827104D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004129 WO2000033869A2 (en) 1998-12-10 1999-12-09 Use of human prostrate cell lines in cancer treatment

Publications (1)

Publication Number Publication Date
IL143296A0 true IL143296A0 (en) 2002-04-21

Family

ID=10843926

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14329699A IL143296A0 (en) 1998-12-10 1999-12-09 Use of human prostate cell lines in cancer treatment
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143296A IL143296A (en) 1998-12-10 2001-05-22 Factor containing a line of prostate cells, preparations containing it and use in the treatment of prostate cancer

Country Status (19)

Country Link
US (3) US6972128B1 (enExample)
EP (1) EP1137422B1 (enExample)
JP (2) JP4949554B2 (enExample)
KR (1) KR20010090874A (enExample)
AT (1) ATE304365T1 (enExample)
AU (1) AU763485B2 (enExample)
CA (1) CA2354045C (enExample)
CZ (1) CZ300499B6 (enExample)
DE (1) DE69927286T2 (enExample)
ES (1) ES2249046T3 (enExample)
GB (1) GB9827104D0 (enExample)
HU (1) HUP0104568A3 (enExample)
IL (2) IL143296A0 (enExample)
MX (1) MXPA01005816A (enExample)
NO (1) NO327044B1 (enExample)
NZ (1) NZ512004A (enExample)
PL (1) PL201016B1 (enExample)
WO (1) WO2000033869A2 (enExample)
ZA (1) ZA200104164B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
AU4935700A (en) * 1999-05-21 2000-12-12 Onyvax Limited New vaccine formulations-3
US7303911B2 (en) * 2000-04-01 2007-12-04 Onyvax Limited Prostate cell lines
US6667479B2 (en) * 2001-06-01 2003-12-23 Raytheon Company Advanced high speed, multi-level uncooled bolometer and method for fabricating same
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US20050180952A1 (en) * 2003-08-26 2005-08-18 Pettis Ronald J. Methods for intradermal delivery of therapeutics agents
JP5239041B2 (ja) * 2007-02-07 2013-07-17 一般財団法人阪大微生物病研究会 癌の治療剤
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
AU2009200767A1 (en) * 2008-03-10 2009-09-24 Aristocrat Technologies Australia Pty Limited A gaming system and a method of gaming
EP2376089B1 (en) * 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607309B1 (en) * 1991-10-04 2003-01-08 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
ATE338813T1 (de) * 1995-03-17 2006-09-15 Univ California Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ES2191784T3 (es) * 1995-12-28 2003-09-16 Univ Johns Hopkins Med Vacunas de tumores de citocinas paracrinas alogenicas.
ATE239781T1 (de) * 1996-02-02 2003-05-15 Us Gov Health & Human Serv Immortalisierte menschliche prostata- epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
PL201016B1 (pl) 2009-02-27
US20120164099A1 (en) 2012-06-28
MXPA01005816A (es) 2002-03-27
DE69927286D1 (de) 2005-10-20
AU763485B2 (en) 2003-07-24
JP2012021028A (ja) 2012-02-02
DE69927286T2 (de) 2006-06-29
CA2354045A1 (en) 2000-06-15
US20050249756A1 (en) 2005-11-10
GB9827104D0 (en) 1999-02-03
ES2249046T3 (es) 2006-03-16
JP4949554B2 (ja) 2012-06-13
WO2000033869A2 (en) 2000-06-15
AU1668300A (en) 2000-06-26
EP1137422A2 (en) 2001-10-04
IL143296A (en) 2006-06-11
CZ20012032A3 (cs) 2001-10-17
NO20012634L (no) 2001-08-08
ATE304365T1 (de) 2005-09-15
PL348828A1 (en) 2002-06-17
WO2000033869A3 (en) 2000-10-12
CA2354045C (en) 2012-02-21
NO20012634D0 (no) 2001-05-29
JP2002531520A (ja) 2002-09-24
HUP0104568A3 (en) 2004-05-28
NZ512004A (en) 2003-08-29
NO327044B1 (no) 2009-04-06
HUP0104568A2 (hu) 2002-03-28
US6972128B1 (en) 2005-12-06
CZ300499B6 (cs) 2009-06-03
US8034360B2 (en) 2011-10-11
ZA200104164B (en) 2002-01-24
EP1137422B1 (en) 2005-09-14
KR20010090874A (ko) 2001-10-19

Similar Documents

Publication Publication Date Title
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA01010982A (es) Uso de phyllanthus para la estimulacion dirigida al objetivo del sistema inmune.
PL348828A1 (en) New cancer treatments
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
BR9808858A (pt) Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos
ZA200003236B (en) Combination therapy for the treatment of migraine.
AU6083301A (en) Treating eczema and/or psoriasis
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
IL131478A0 (en) Methods for treatment of scar tissue
IL139144A0 (en) Mycobacterial inhibitors
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
ES2169986A1 (es) Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
ZA200002343B (en) Combination therapy for the treatment of migraine.
IL148336A (en) Medicaments that contain xenogeneic oligo and/or polyribonucleotides
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
UA33537A (uk) Пристрій для масажу в су-джок терапії

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed